Tech Company Financing Transactions
Ten63 Therapeutics Funding Round
Ten63 Therapeutics closed a funding round on 2/19/2026. Investors included Alexandria Venture Investments, Bill & Melinda Gates Foundation and Black Opal Ventures.
Transaction Overview
Company Name
Announced On
2/19/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance of its proprietary computational drug discovery platform, BEYOND.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Durham Fwy
Durham, NC Undisclosed
USA
Durham, NC Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Ten63 is pushing the boundaries of computational drug discovery to design first and best-in-class therapeutics with enhanced durability against previously undruggable targets. Our BEYOND platform allow us to design potent chemistry against the hardest targets by searching previously unexplored, drug-like, synthetically accessible chemical space.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Bruce Donald
Chief Executive Officer
Marcel Frenkel
Chief Technical Officer
Mark Hallen
Co-Founder
Nancy Rich
Browse more venture capital transactions:
Prev: 2/19/2026: Unicity Labs venture capital transaction
Next: 2/19/2026: DailyPay venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC transactions on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs